'Pharma Bro' Martin Shkreli has launched a newsletter to talk investing, science, and tech a month after his release from prison

Advertisement
'Pharma Bro' Martin Shkreli has launched a newsletter to talk investing, science, and tech a month after his release from prison
In this Feb. 4, 2016 file photo, Pharmaceutical chief Martin Shkreli smiles on Capitol Hill in Washington.AP Photo/Susan Walsh
  • Former pharmaceutical executive Martin Shkreli launched a tech and investing newsletter Thursday.
  • The first entry of "Martin's Newsletter" was subtitled "This post was written in prison."
Advertisement

Martin Shkreli has a Substack.

The former pharmaceutical exec and "Pharma Bro" launched his tech and investing newsletter on Thursday, just over a month after he was released from prison having served less than five years of his seven-year sentence.

Shkreli is now living in a halfway house pending his planned release in September.

Complimentary Tech Event
Discover the future of SaaS in India
The 6-part video series will capture the vision of Indian SaaS leaders and highlight the potential for the sector in the decades to come.Watch on Demand
Our Speakers
Girish Mathrubootham
Brian E. Taptich

The first entry of Martin's Newsletter, subtitled "This post was written in prison," is a rambling collection of book reviews, predictions, and musings, including whether he would be un-banned from Twitter.

By 2025, for example, he projects "TSLA nears $10T market cap, Musk becomes the first trillionaire."

Advertisement

The newsletter arrived amid a pitched proxy battle between Shkreli and a group of activist investors seeking to take control of his pharmaceutical firm Turing.

A lawyer for Shkreli declined to comment when contacted by Insider.

Shkreli was found guilty of securities fraud in 2017 and faced a separate antitrust lawsuit for raising the price of the rare, life-saving anti-parasitic drug Daraprim by 5,000%.

Earlier this year, a federal judge barred him from the pharmaceutical industry for life and ordered him to pay a $64.6 million fine.

As for the newsletter, Shkreli said that it wouldn't be free and, in a nod to his infamous raising of Daraprim, said: "Expect a 5000% price increase soon. Just don't mix up relative and absolute changes. That's been a matter of confusion in the past."

Advertisement

Brent Hodge, who directed the "Pharma Bro" documentary, told the New York Post that Shkreli "likes to play up his position as a supervillain."

{{}}